Braxia Scientific has received approval from Health Canada to provide psilocybin-assisted psychotherapy for a patient with Major Depressive Disorder (MDD) in Ontario.
The psilocybin-assisted therapy will be delivered through Braxia’s wholly owned subsidiary Canadian Rapid Treatment Centre of Excellence (CRTCE).
The approval is Braxia‘s first psilocybin-assisted therapy treatment using Health Canada’s SAP, however, the company was the first to receive Health Canada approval for a multi-dose psilocybin-assisted therapy clinical trial in July 2021.
Chief Medical and Scientific Officer at Braxia Scientific, Dr Joshua Rosenblat, commented: “Being among the first to begin delivering psilocybin-assisted therapy treatments in Canada last year through our clinical trial, we have developed and optimised the infrastructure, including rigorous training for our therapists through our Braxia Institute, to provide a positive patient experience while optimising outcomes.”
“To our knowledge, this is the first Health Canada SAP approval for psilocybin-assisted therapy for a person with Major Depressive Disorder in Ontario.
“My patient and I are extremely grateful for this opportunity to access this promising treatment. Health Canada was very responsive to this request, promptly providing the Letter of Authorization.
“This rapid approval stands in contrast to the previously required Section 56 exemptions that could take years to fully process. Allowing use of the SAP will be incredibly beneficial for patients in need of this treatment that are unable to receive it through psychedelic clinical trials.”
Chairman and CEO of Braxia Scientific, Dr Roger McIntyre, commented: “Since opening our first clinic in 2018, in Toronto, Canada, our focus has been on creating a true centre of excellence for people living and suffering with depression to gain access to the most effective treatments.
“Our ability to deliver psilocybin-assisted therapy is an important step in our journey to achieving our vision of finding a cure for depression.
“The experience of our therapists who have already delivered this novel treatment in multiple doses to multiple patients in our ongoing psilocybin trial, combined with data we’ve collected to date and expect to read out in the coming weeks, provides an excellent opportunity for new applicants to receive access to the most advanced clinical protocols and care to achieve best outcomes in this field.
“In addition to providing access to innovative treatments for depression, Braxia Scientific is a leader in comprehensive research, development and best-practices implementation of psilocybin, ketamine and related agents.”
[activecampaign form=52]
